This work should prompt additional basic, translational, and clinical studies evaluating early adipogenic signaling, IGF-1, and related metabolic dysregulation in patients with ARVC mutations. The gene discussed is IGF1; the disease is Arrhythmogenic right ventricular dysplasia.